 |
recombinant fusion protein comprising exenatide and XTEN |
|---|---|
| Trade Name | |
| Orphan Indication | Short bowel syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2015-10-07 00:00:00 |
| Sponsor | NAIA Pharmaceuticals, Inc.;215 McAllister Avenue;Kentfield, California, 94904 |
